fda approved semaglutide compound Novo asks to prevent compounders from making GLP-1 knockoffs Compounded Semaglutide & Tirzepatide 2025:

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide in Japanese Patients With Type 2 Diabetes (PIONEER 10): An Open-Label, Randomised, Active-Controlled, Phase 3a Trial

Fresh semaglutide solution is typically clear and colorless, though some formulations with B12 may have a slight pink or reddish tint

The focus on b12 specifically appears to be marketing rather than science

Retatrutide is an investigational drug and not approved by the FDA for any indication as of May 2026

Retatrutide is an investigational triple agonist peptide (GIP, GLP-1, and glucagon receptor) currently under clinical development for the management of obesity and type 2 diabetes

ECs in the gut produce ~95% of the 5-HT in the body, which is presumed to act on 5-HT receptors expressed on local gut neurons 289